Good Day BIO Newsletter

What a week. We start a new one with a look at the latest news on avian flu and AMR, plus what’s ahead in Washington (including a PBM hearing tomorrow). (805 words, 4 minutes, 1 second)

Back so soon? We have a lot to share, with FDA’s announcement of a Rare Disease Innovation Hub plus more benefits of COVID-19 vaccines and the latest data on global childhood vaccination rates. (528 words, 2 minutes, 38 seconds)P.S. It’s not too late to complete the 3-minute reader survey and weigh in on BIO’s media content and communications! 

While we get ready to evolve to a new format for the rest of the summer, we feel like it’s a good day to check in on COVID-19 and how far we’ve come—thanks to the biotech industry’s efforts we’ve been covering for 4+ years. Plus, a proposed rule change from CMS represents a positive step toward better patient access to cutting-edge Alzheimer’s treatments. (624 words, 3 minutes, 7 seconds)

Good Day BIO is evolving. Over the summer, Bio.News will bring you a weekly digest every Monday at 10 A.M. ET, plus breaking news alerts as needed. This transition period will allow us to analyze feedback and analytics and develop even better communications to meet your needs. This week: BIO Board member Frank Watanabe's testimony at a House hearing, an exclusive interview with Sen. Richard Burr on the legacy of Project BioShield, the latest on bird flu and PBMs, and how you can follow the RNC,…

We have details on BIO’s comments on a U.S. Patent and Trademark Office proposal that would harm the patent system—plus, more groundbreaking companies featured at the NIH Innovation Zone at BIO 2024 and how to nominate a leader for the California Life Sciences Pantheon Awards. Don’t forget to take our reader survey! (623 words, 3 minutes, 6 seconds)

At long last, the FTC released an interim report on PBMs—and the findings are not surprising. We have details, plus more about the winners of BIO’s 2024 Agri-Biotechnology Awards. Don’t forget to take our reader survey! (523 words, 2 minutes, 36 seconds)

Today, we have news on Boehringer Ingelheim’s new biomass power plant and the expanding range of lone star ticks—plus, how you can weigh in on what’s next for BIO’s communications products. (731 words, 3 minutes, 39 seconds)

Congress heads back to work, and we catch up on news including the FDA’s approval of Eli Lilly’s Alzheimer’s drug and what happened at the U.S.-Mexico-Canada Agreement dispute panel on Mexico’s biotech corn ban. (618 words, 3 minutes, 5 seconds)We want your feedback! We are conducting a survey to get reader feedback on the Good Day BIO newsletter and ensure our content best meets your needs. Click here to take our short survey.

Before we head out for the holiday week, we have more on the CDC’s new recommendations for respiratory diseases, a new analysis of the Inflation Reduction Act’s impacts, and a look at two biotech innovators to watch. (659 words, 3 minutes, 17 seconds)We’re taking a publishing break for the July 4 holiday week. We will return on Monday, July 8. In the meantime, keep an eye on Bio.News for breaking news.

Eli Lilly teams up with OpenAI to fight AMR—another way AI could transform biotech. Plus, dengue is surging worldwide, and the CDC says it now threatens the U.S.—but biotech and One Health could help. (512 words, 2 minutes, 33 seconds)